Advertisement

Topics

Cardiovascular implications of newer obesity medications

07:46 EDT 18 Oct 2016 | Healio

Obesity affects more than 30% of adults in the United States and directly contributes to increased risk for cardiovascular disease. Lifestyle interventions are the mainstay of treatment, but pharmacotherapy may be considered as an adjunct for adults with a BMI of at least 30 kg/m2 or a BMI of at least 27 kg/m2 with one or more obesity-related comorbidities.Withdrawal of antiobesity medications from the U.S. market (eg, fenfluramine, dexfenfluramine, sibutramine) has been primarily associated with drug-related adverse CV events. Until recently, the only medications approved for weight management include sympathomimetic amines (eg, phentermine) and orlistat (Alli, GlaxoSmithKline; Xenical, Hoffmann-La Roche), a lipase inhibitor. We review the CV implications of four newer agents approved for chronic weight management since 2012.

Original Article: Cardiovascular implications of newer obesity medications

NEXT ARTICLE

More From BioPortfolio on "Cardiovascular implications of newer obesity medications"

Quick Search
Advertisement
 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...